{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:02:59Z","timestamp":1791669779550,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jaip.2024.10.045","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T17:17:53Z","timestamp":1730999873000},"page":"551-558.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Pharmacovigilance Analysis of Post-Marketing Safety of Tezepelumab"],"prefix":"10.1016","volume":"13","author":[{"given":"Huqun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongshu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuilian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.10.045_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2024.10.045_bib2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.10.045_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/ACI.0000000000000623","article-title":"Severe asthma: what is new in the new millennium","volume":"20","author":"Ntontsi","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.10.045_bib4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","article-title":"Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma","volume":"24","author":"Gauvreau","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaip.2024.10.045_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaip.2024.10.045_bib6","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.10.045_bib7","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.4049\/jimmunol.1701455","article-title":"Elevated expression of IL-33 and TSLP in the airways of human asthmatics in\u00a0vivo: a potential biomarker of severe refractory disease","volume":"200","author":"Li","year":"2018","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2024.10.045_bib8","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.10.045_bib9","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.10.045_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/JAA.S288260","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma with and without nasal polyposis: a post hoc analysis of the phase 2b PATHWAY study","volume":"14","author":"Emson","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2024.10.045_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02202-2022","article-title":"Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond","volume":"61","author":"Corren","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.10.045_bib12","article-title":"The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: a systematic review and meta-analysis of randomized controlled trials","volume":"102","author":"Lin","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2024.10.045_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.10.045_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11882-017-0686-1","article-title":"Mechanisms driving gender differences in asthma","volume":"17","author":"Fuseini","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2024.10.045_bib17","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.3390\/ijms25115972","article-title":"Thymic stromal lymphopoietin and tezepelumab in airway diseases: from physiological role to target therapy","volume":"25","author":"Bagnasco","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2024.10.045_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","article-title":"Tezepelumab: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jaip.2024.10.045_bib19","first-page":"613","article-title":"Cardiovascular events in men with prostate cancer receiving hormone therapy: an analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"206","author":"Zhang","year":"2021","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jaip.2024.10.045_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18176\/jiaci.0949","article-title":"Positioning of tezepelumab in severe asthma","volume":"34","author":"Miralles-L\u00f3pez","year":"2024","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2024.10.045_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1280490","article-title":"A\u00a0real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2024.10.045_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-2600(19)30372-8","volume":"8","author":"Bernstein","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.10.045_bib23","first-page":"1","article-title":"Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS)","author":"Zou","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaip.2024.10.045_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1320458","article-title":"A\u00a0real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2024.10.045_bib25","article-title":"The impact of tezepelumab in uncontrolled severe asthma: a systematic review of randomized controlled trials","volume":"14","author":"Roy","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2024.10.045_bib26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cpt.1401","article-title":"Pharmacokinetics, safety, and tolerability of tezepelumab (AMG 157) in healthy and atopic dermatitis adult subjects","volume":"106","author":"Parnes","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2024.10.045_bib27","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.10.045_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12038","article-title":"Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2024.10.045_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1590\/1806-9282.20221358","article-title":"Anaphylactic risks associated with immunobiological agents in asthma therapy","volume":"69","author":"Baddini-Martinez","year":"2023","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"21","key":"10.1016\/j.jaip.2024.10.045_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12931-020-01503-z","article-title":"SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma","volume":"13","author":"Wechsler","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2024.10.045_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003583","article-title":"Anti-IL-5 biologics and rheumatoid arthritis: a single-centre 500 patient year exposure analysis","volume":"9","author":"Dean","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jaip.2024.10.045_bib32","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1080\/02770903.2021.2008431","article-title":"Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review","volume":"59","author":"Israel","year":"2022","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2024.10.045_bib33","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/JAA.S342993","article-title":"Development of rheumatoid arthritis during anti-interleukin-5 therapy in a patient with refractory chronic eosinophilic pneumonia","volume":"14","author":"Kawabata","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2024.10.045_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3897\/folmed.65.e72448","article-title":"Rheumatoid arthritis and the proinflammatory cytokine IL-17","volume":"65","author":"Selimov","year":"2023","journal-title":"Folia Med (Plovdiv)"},{"key":"10.1016\/j.jaip.2024.10.045_bib35","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1517\/14728222.2014.915314","article-title":"Thymic stromal lymphopoietin: a central regulator of allergic asthma","volume":"18","author":"Watson","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaip.2024.10.045_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40264-014-0146-y","article-title":"Performance of probabilistic method to detect duplicate individual case safety reports","volume":"37","author":"Tregunno","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2024.10.045_bib38","article-title":"Cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on FAERS","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2024.10.045_bib39","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.jaip.2023.01.027","article-title":"Differences in hypersensitivity reactions to iodinated contrast media: analysis of the US Food and Drug Administration Adverse Event Reporting System Database","volume":"11","author":"Lin","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.10.045_bib40","article-title":"Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2024.10.045_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1283247","article-title":"Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2024.10.045_bib42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jclinepi.2023.08.010","article-title":"Pharmacovigilance studies\u00a0without a priori hypothesis: systematic review highlights inappropriate multiple testing correction procedures","volume":"162","author":"Gaucher","year":"2023","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jaip.2024.10.045_bib43","article-title":"Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2024.10.045_bib44","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1517\/14740338.2014.915938","article-title":"A\u00a0comparison of disproportionality analysis methods in national adverse drug reaction databases of China","volume":"13","author":"Hou","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaip.2024.10.045_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1383212","article-title":"Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database","volume":"15","author":"Fu","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824011644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824011644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T03:08:53Z","timestamp":1744686533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824011644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2213219824011644"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.10.045","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Pharmacovigilance Analysis of Post-Marketing Safety of Tezepelumab","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.10.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}